2003•Unpublished venueRequires access

Comparision of Efficacies of Radix Astragali and Losartan on Diabetic Nephropathy During Clinical Stage

Jing Jie

Open publisher page 0 citations

Abstract

Objective To compare the efficacies of RA and losartan on diabetic nephropathy during clinical stage 68 patients with diabetic nephropathy during clinical stage who were good controlled in blood glucose,blood pressure in clinical periods,were randomly divided into losartan group( n =24),RA group( n =26) and diabetic nephropathy group( n =18) the treatment course was 8 weeks.Methods .Results ⑴24h urine albumin,uraneprotein,urine β-microglobulin(β-MG) in 24h were all reduced (all P 0.01),glomerular filtration rate(GFR) was increased in lasartan group after treatment,⑵RA treatment significant decreased urine albumin,protein and urine β-MG in 24h(all P 0.01),elevated GFR( P 0.01)its effect was obviously stronger than that of losartan,⑶In diabetic nephropathy control group,these marker have not obviously alteration.Conclusion Radix Astragali is a better efficient treatment agent for diabetic nephropathy in clinical stage

About this research paper

What this paper is about

Objective To compare the efficacies of RA and losartan on diabetic nephropathy during clinical stage 68 patients with diabetic nephropathy during clinical stage who were good controlled in blood glucose,blood pressure in clinical periods,were randomly divided into losartan group( n =24),RA group( n =26) and diabetic nephropathy group( n =18) the treatment course was 8 weeks.Methods .Results ⑴24h urine albumin,uraneprotein,urine β-microglobulin(β-MG) in 24h were all reduced (all P 0.01),glomerular filtration rate(GFR) was increased in lasartan group after treatment,⑵RA treatment significant decreased urine albumin,protein and urine β-MG in 24h(all P 0.01),elevated GFR( P 0.01)its effect was obviously stronger than that of losartan,⑶In diabetic nephropathy control group,these marker have not obviously alteration.Conclusion Radix Astragali is a better efficient treatment agent for diabetic nephropathy in clinical stage

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To compare the efficacies of RA and losartan on diabetic nephropathy during clinical stage 68 patients with diabetic nephropathy during clinical stage who were good controlled in blood glucose,blood pressure in clinical periods,were randomly divided into losartan group( n =24),RA group( n =26) and diabetic nephropathy group( n =18) the treatment course was 8 weeks.Methods .Results ⑴24h urine albumin,uraneprotein,urine β-microglobulin(β-MG) in 24h were all reduced (all P 0.01),glomerular filtration rate(GFR) was increased in lasartan group after treatment,⑵RA treatment significant decreased urine albumin,protein and urine β-MG in 24h(all P 0.01),elevated GFR( P 0.01)its effect was obviously stronger than that of losartan,⑶In diabetic nephropathy control group,these marker have not obviously alteration.Conclusion Radix Astragali is a better efficient treatment agent for diabetic nephropathy in clinical stage

Key concepts: Losartan, Diabetic nephropathy, Medicine, Urology, Renal function, Urine, Internal medicine, Nephropathy

Related papers

Back to paper searchBrowse research topicsOriginal source
Comparision of Efficacies of Radix Astragali and Losartan on Diabetic Nephropathy During Clinical Stage — Research Paper | ScholarLens